Welcome to our dedicated page for Atara Biotherapeutics news (Ticker: ATRA), a resource for investors and traders seeking the latest updates and insights on Atara Biotherapeutics stock.
Atara Biotherapeutics, Inc (Symbol: ATRA) is a pioneering company in the healthcare sector, specializing in the development of transformative therapies for patients combating serious diseases, including cancer, kidney disease, and autoimmune disorders. Founded in August 2012, Atara Biotherapeutics is driven by a mission to provide better treatment options for patients, inspired by Atara Ciechanover, who tragically passed away from cancer in 2012.
The company's research is founded on groundbreaking discoveries related to activin, myostatin, and other growth factors that can alter disease progression. Atara's innovative approach has led to the development of several promising product candidates:
- Pinta 745
- STM 434
- ATA 842
Moreover, Atara Biotherapeutics is collaborating with the prestigious Memorial Sloan Kettering Cancer Center (MSK) to develop three cutting-edge T-cell product candidates:
- Epstein-Barr Virus (EBV)-targeted Cytotoxic T Lymphocytes (CTLs)
- Cytomegalovirus (CMV)-targeted CTLs
- Wilms Tumor 1 (WT1)-targeted CTLs
These T-cell therapies are designed to tackle the underlying mechanisms of various diseases, offering hope for conditions that are currently challenging to treat.
Atara's product pipeline also includes Tab-cel, ATA188, and ATA3219 (CAR T platform). Each of these candidates targets specific mechanisms of disease, aiming to provide effective and innovative treatment solutions.
The company operates within the US healthcare sector, managing its business as a single operating and reportable segment focused on therapeutic development. Atara Biotherapeutics continues to make strides in its mission, marked by recent achievements and partnerships that underscore its commitment to improving patient outcomes.
Stay updated with the latest news and developments from Atara Biotherapeutics to gain insights into their ongoing projects and performance in the stock market.
Atara Biotherapeutics (Nasdaq: ATRA) announced the grant of 66,800 restricted stock units to six new employees and stock options for 40,000 shares to one employee, approved by its Compensation Committee. The awards were granted under the 2018 Inducement Plan with a grant date of January 3, 2022. The restricted stock units will vest over four years, while the stock options will have a ten-year term with an exercise price of $3.28, equivalent to the January 3, 2022, closing price. Atara focuses on developing T-cell immunotherapies for cancer and autoimmune diseases, having received marketing authorization for its lead program in Europe.
Atara Biotherapeutics (NASDAQ: ATRA) announced that CEO Pascal Touchon will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 3:45 PM PST in San Francisco. The company specializes in T-cell immunotherapy, focusing on treatments for cancer and autoimmune diseases, utilizing its allogeneic EBV T-cell platform. A live audio webcast of the presentation will be accessible on their website, along with an archived replay available for 30 days post-event.
Atara Biotherapeutics (ATRA) has secured a $31 million royalty interest financing agreement with HealthCare Royalty for its therapy, Ebvallo™, in Europe. This agreement is expected to extend Atara's cash runway and includes specified royalties and milestones linked to its commercialization partnership with Pierre Fabre. Additional milestones of $40 million from Pierre Fabre are also anticipated. The deal is seen as a strategic move to bolster Atara's financial position following the recent European approval of Ebvallo™ for treating a rare cancer.
Atara Biotherapeutics, Inc. announced that Carol Gallagher will replace Ron Renaud as Chair of the Board of Directors. Gallagher, a seasoned public company director, brings extensive experience, having served on Atara's Board since 2013. Renaud stepped down to focus on his new role at Bain Capital Life Sciences. Additionally, Roy Baynes will also leave the Board to pursue other opportunities. Atara’s President, Pascal Touchon, expressed confidence in Gallagher's leadership as the company continues to develop its EBV T-cell therapies aimed at serious diseases.
Atara Biotherapeutics (NASDAQ: ATRA) receives European Commission approval for Ebvallo™ (tabelecleucel) to treat patients with EBV+ PTLD. This marks the first approval of an allogeneic T-cell immunotherapy globally.
Ebvallo™ is indicated for patients aged over two years with relapsed or refractory EBV+ PTLD who have had prior therapy. The approval comes after a positive opinion from the EMA’s CHMP, based on pivotal Phase 3 ALLELE study results.
Pierre Fabre will handle commercialization in Europe, benefiting patients facing a median survival of less than four months.
Atara Biotherapeutics announced interim results from its Phase 3 ALLELE study of tabelecleucel (tab-cel) for treating relapsed/refractory EBV+ PTLD. The study showed a 51.2% objective response rate in 43 patients, with a median duration of response of 23.0 months and median overall survival of 18.4 months. Results were presented at the 64th American Society of Hematology Annual Meeting. Tab-cel demonstrated potential in treating previously unaddressed EBV+ conditions, suggesting a significant market opportunity for Atara.
Atara Biotherapeutics (NASDAQ: ATRA) has announced the grant of 33,150 restricted stock units and 13,375 stock options to newly hired employees, aimed at incentivizing talent. The restricted stock units will vest over four years, while the stock options have a ten-year term with an exercise price set at $4.40. This action aligns with Nasdaq Listing Rule 5635(c)(4) to attract employees critical for the company's focus on T-cell immunotherapy. Atara continues to push forward its EBV T-cell platform for treating serious diseases.
Atara Biotherapeutics (NASDAQ: ATRA) announced that its CEO, Pascal Touchon, will engage in a virtual fireside chat at the Evercore ISI 5th Annual HealthCONx Conference on November 30, 2022, at 2:15 p.m. EST. The event will focus on Atara's advancements in T-cell immunotherapy, particularly its allogeneic Epstein-Barr virus (EBV) T-cell platform. Attendees can access a live webcast on atarabio.com, with an archived version available for 30 days post-event.
Atara Biotherapeutics (NASDAQ: ATRA) announced that its Chief Medical Officer, AJ Joshi, and Chief Financial Officer, Utpal Koppikar, will participate in a fireside chat at the Stifel Healthcare Conference in New York on November 16, 2022, at 1:50 p.m. EST. A live webcast will be available on atarabio.com, with an archived replay accessible for 30 days. Atara is pioneering T-cell immunotherapy targeting conditions like cancer and autoimmune diseases, leveraging its unique allogeneic Epstein-Barr virus T-cell platform.
Atara Biotherapeutics reported significant progress in T-cell immunotherapy, highlighted by a positive CHMP opinion for its product Ebvallo™ for treating EBV+ PTLD. The EMA's endorsement positions it as the first allogeneic T-cell therapy potentially approved by the end of 2022. Financially, Atara reported a net loss of $84.1 million, with cash reserves of $265.4 million as of September 30, 2022. The company also presented promising data on ATA188 for progressive MS, showing less brain atrophy and potential remyelination. A conference call is scheduled for November 8, 2022.
FAQ
What is the current stock price of Atara Biotherapeutics (ATRA)?
What is the market cap of Atara Biotherapeutics (ATRA)?
What does Atara Biotherapeutics, Inc specialize in?
When was Atara Biotherapeutics founded?
Who is Atara Ciechanover?
What are some of Atara's key product candidates?
With which institution is Atara Biotherapeutics collaborating?
What types of T-cell therapies is Atara developing?
What is the mission of Atara Biotherapeutics?
Where does Atara Biotherapeutics operate?
What are activin and myostatin in the context of Atara's research?
How does Atara manage its business operations?
